var data={"title":"Octreotide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Octreotide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6674?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">see &quot;Octreotide: Drug information&quot;</a> and <a href=\"topic.htm?path=octreotide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Octreotide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202953\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>SandoSTATIN;</li>\n      <li>SandoSTATIN LAR Depot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202954\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ocphyl;</li>\n      <li>Octreotide Acetate Omega;</li>\n      <li>Octreotide Injection;</li>\n      <li>Sandostatin;</li>\n      <li>Sandostatin LAR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060641\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiarrheal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihemorrhagics</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antisecretory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Somatostatin Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675255\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chylothorax:</b> Continuous IV infusion: 0.3-10 mcg/kg/<b>hour</b> titrated to response (median: 2.8 mcg/kg/<b>hour</b>) has been described in case reports; treatment duration is usually 1-3 weeks but may vary with the clinical response (Das, 2010; Roehr, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Persistent hyperinsulinemic hypoglycemia of infancy</b>  (Stanley, 1997): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial: 0.08-0.4 mcg/kg/<b>hour</b>; titrate dosage depending upon patient response; maximum dose: 1.67 mcg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Initial: 2-10 mcg/kg/day divided 3-4 times daily; titrate dosage depending upon patient response; maximum daily dose: 40 mcg/kg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060634\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">see &quot;Octreotide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be individualized according to the patient's response </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Sandostatin&reg;:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children (data limited to small studies and case reports): <b>Note:</b> The following are effective dosing ranges for specific therapies: IV, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Diarrhea:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous IV infusion: Initial: 1 mcg/kg bolus dose, followed by a continuous infusion of 1 mcg/kg/<b>hour</b> has been used successfully in several cases of severe diarrhea secondary to graft vs host disease </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV, SubQ: Doses of 1-10 mcg/kg/dose every 12 hours have been used in children beginning at the low end of the range and increasing based upon the clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chylothorax:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous IV infusion: 0.3-10 mcg/kg/<b>hour</b> titrated to response (median: 2.8 mcg/kg/<b>hour</b>) has been described in case reports; treatment duration is usually 1-3 weeks but may vary with the clinical response (Roehr, 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">SubQ: 40 mcg/kg/day; case reports of effective dosage range from 2-68 mcg/kg/day (Chan, 2006; Roehr, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Esophageal varices/GI bleed: 1-2 mcg/kg initial IV bolus followed by 1-2 mcg/kg/<b>hour</b> continuous infusion; titrate infusion rate to response; taper dose by 50% every 12 hours when no active bleeding occurs for 24 hours; may discontinue when dose is 25% of initial dose (Eroglu, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hypothalamic obesity (from cranial insult): SubQ: 5 mcg/kg/day divided into 3 daily doses; dose may be increased bimonthly at 5 mcg/kg/day increments to a maximum of 15 mcg/kg/day divided into 3 daily doses (Lustig, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Persistent hyperinsulinemic hypoglycemia of infancy: SubQ: 2-10 mcg/kg/day divided 3-4 times daily; titrate dosage depending upon patient response; maximum daily dose: 40 mcg/kg/day (Stanley, 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Treatment of sulfonylurea overdose: <b>Note:</b> SubQ is the preferred route of administration; repeat dosing, dose escalation, or initiation of a continuous infusion may be required in patients who experience recurrent hypoglycemia. Duration of treatment may exceed 24 hours. Optimal care decisions should be made based upon patient-specific details; SubQ: 1-1.5 mcg/kg/dose; repeat in 6-12 hours as needed based upon blood glucose concentrations </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Acromegaly:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">SubQ, IV: Initial: 50 mcg 3 times/day; titrate to achieve growth hormone levels &lt;5 ng/mL or IGF-I (somatomedin C) levels &lt;1.9 units/mL in males and &lt;2.2 units/mL in females. Usual effective dose is 100-200 mcg 3 times/day; range: 300-1500 mcg/day. <b>Note:</b> Should be withdrawn yearly for a 4-week interval (8 weeks for depot injection) in patients who have received irradiation. Resume if levels increase and signs/symptoms recur.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM depot injection: Patients must be stabilized on subcutaneous octreotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg IM intragluteally every 4 weeks for 3 months, then the dose may be modified based upon response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Dosage adjustment:</i> After 3 months of depot injections, the dosage may be continued or modified as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">GH &le;1 ng/mL, IGF-1 normal, and symptoms controlled: Reduce octreotide LAR&reg; to 10 mg IM every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">GH &le;2.5 ng/mL, IGF-1 normal, and symptoms controlled: Maintain octreotide LAR&reg; at 20 mg IM every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">GH &gt;2.5 ng/mL, IGF-1 elevated, and/or symptoms uncontrolled: Increase octreotide LAR&reg; to 30 mg IM every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <b>Note:</b> Patients not adequately controlled at a dose of 30 mg may increase dose to 40 mg every 4 weeks. Dosages &gt;40 mg are not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Carcinoid tumors:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">SubQ, IV: Initial 2 weeks: 100-600 mcg/day in 2-4 divided doses; usual range: 50-750 mcg/day (some patients may require up to 1500 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM depot injection: Patients must be stabilized on subcutaneous octreotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg IM intragluteally every 4 weeks for 2 months, then the dose may be modified based upon response</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <b>Note:</b> Patients should continue to receive their SubQ injections for the first 2 weeks at the same dose in order to maintain therapeutic levels (some patients may require 3-4 weeks of continued SubQ injections). Patients who experience periodic exacerbations of symptoms may require temporary SubQ injections in addition to depot injections (at their previous SubQ dosing regimen) until symptoms have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Dosage adjustment:</i> See dosing adjustment for VIPomas.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">VIPomas:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">SubQ, IV: Initial 2 weeks: 200-300 mcg/day in 2-4 divided doses; titrate dose based on response/tolerance; range: 150-750 mcg/day (doses &gt;450 mcg/day are rarely required) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM depot injection: Patients must be stabilized on subcutaneous octreotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg IM intragluteally every 4 weeks for 2 months, then the dose may be modified based upon response.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <b>Note:</b> Patients receiving depot injection should continue to receive their SubQ injections for the first 2 weeks at the same dose in order to maintain therapeutic levels (some patients may require 3-4 weeks of continued SubQ injections). Patients who experience periodic exacerbations of symptoms may require temporary SubQ injections in addition to depot injections (at their previous SubQ dosing regimen) until symptoms have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Dosage adjustment:</i> After 2 months of depot injections, the dosage may be continued or modified as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Increase to 30 mg IM every 4 weeks if symptoms are inadequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Decrease to 10 mg IM every 4 weeks, for a trial period, if initially responsive to 20 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Dosage &gt;30 mg is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> Clearance is decreased by 50% in patients with severe renal failure requiring dialysis; consider dosage modification in these patients as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nondialysis-dependent renal impairment: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dialysis-dependent renal impairment: Depot injection: Initial dose: IM: 10 mg every 4 weeks; titrate based upon response (clearance is reduced by ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Patients with established cirrhosis of the liver: Depot injection: Initial dose: IM: 10 mg every 4 weeks; titrate based upon response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202929\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandoSTATIN LAR Depot: 10 mg, 20 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandoSTATIN: 50 mcg/mL (1 mL); 100 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandoSTATIN: 200 mcg/mL (5 mL [DSC]) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandoSTATIN: 500 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandoSTATIN: 1000 mcg/mL (5 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mcg/mL (1 mL); 100 mcg/mL (1 mL); 200 mcg/mL (5 mL); 1000 mcg/5 mL (5 mL); 500 mcg/mL (1 mL); 1000 mcg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/mL (1 mL); 500 mcg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202915\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060645\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Only Sandostatin injection may be administered IV and SubQ; Sandostatin LAR Depot may only be administered IM</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ: Use the concentration with smallest volume to deliver dose to reduce injection site pain; rotate injection site; may bring to room temperature prior to injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV infusion: Dilute Sandostatin injection and infuse over 15 to 30 minutes or over 24 hours as a continuous infusion; in emergency situations, may be administered undiluted by direct IV push over 3 minutes; allow solution to come to room temperature before administration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer into gluteal area only; avoid deltoid injections due to significant pain and discomfort at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202949\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection solution: Octreotide is a clear solution and should be stored at refrigerated temperatures between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F). Protect from light. May be stored at room temperature of 20&deg;C to 30&deg;C (68&deg;F and 86&deg;F) for up to 14 days when protected from light. Stable as a parenteral admixture in NS or D5W for 24 hours. Discard multidose vials within 14 days after initial entry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LAR depot suspension: Prior to dilution, store at refrigerated temperatures between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F). Protect from light. Additionally, the manufacturer reports that octreotide suspension may be stored at room temperature of 20&deg;C to 25&deg;C (68&deg;F and 77&deg;F) for up to 10 days when protected from light (data on file [Novartis 2011]). Depot drug product kit may be at room temperature for 30 to 60 minutes prior to use. Use suspension immediately after preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060644\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Control of symptoms, including secretory diarrhea in patients with metastatic carcinoid or vasoactive intestinal peptide-secreting tumors (VIPomas) (FDA approved in adults); treatment of acromegaly (FDA approved in adults). Other uses include control of bleeding of esophageal varices, Cushing's syndrome, insulinomas, glucagonoma, small bowel fistulas, postgastrectomy dumping syndrome, chemotherapy-induced diarrhea, graft-versus-host disease (GVHD)-associated diarrhea, Zollinger-Ellison syndrome, persistent hyperinsulinemic hypoglycemia of infancy (nesidioblastosis), postoperative chylothorax, second-line treatment for thymic malignancies; islet cell tumors; treatment of malignant bowel obstruction; treatment of sulfonylurea overdosage (nondepot formulation); hypothalamic obesity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203010\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Octreotide may be confused with lanreotide, pasireotide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">SandoSTATIN may be confused with SandIMMUNE, SandoSTATIN LAR, sargramostim, simvastatin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370122\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions vary by route of administration or dosage form.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac conduction disturbance, cardiac failure, chest pain (non-depot formulations), edema, flushing, hypertension, palpitations, peripheral edema, phlebitis, sinus bradycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, amnesia, anxiety, confusion, depression, dizziness, drowsiness, fatigue, hallucination, headache, hypertonia, hypoesthesia, insomnia, malaise, nervousness, neuralgia, neuropathy, pain, paresthesia, rigors, vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, diaphoresis, pruritus, skin rash (depot formulation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Albuminuria, cachexia, goiter (non-depot formulations), gout, hyperglycemia, hypoglycemia, hypokalemia, hypothyroidism (non-depot formulations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, biliary obstruction (duct dilatation), cholelithiasis (length of therapy-dependent), colitis, constipation, diarrhea, diverticulitis, dysgeusia, dyspepsia, dysphagia, fecal discoloration, flatulence, gallbladder sludge (length of therapy-dependent), gastritis, gastroenteritis, gingivitis, glossitis, loose stools, malabsorption (fat), melena, nausea, steatorrhea, stomatitis, tenesmus, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, mastalgia, pollakiuria (non-depot formulations), urinary incontinence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (non-depot formulations), bruise, hematoma, hypoproteinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (to octreotide; no efficacy change)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess (renal), bacterial infection, candidiasis, cold symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Hematoma at injection site, pain at injection site (formulation-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, hyperkinesia, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephrolithiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea (non-depot formulations), epistaxis, flu-like symptoms, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Adrenocortical insufficiency, amenorrhea, anaphylactic shock, anaphylactoid reaction, aneurysm, aphasia, appendicitis, arthritis, ascites, atrial fibrillation, basal cell carcinoma, Bell's palsy, biliary obstruction, breast carcinoma, cardiac failure, cerebrovascular disease, cholangitis (ascending), cholecystitis, cholestatic hepatitis, cyanocobalamin deficiency, deafness, decreased libido, diabetes insipidus, diabetes mellitus, erythema (with wheal), facial edema, galactorrhea, gastrointestinal hemorrhage, gastrointestinal ulcer, glaucoma, gynecomastia, hematuria, hemiparesis, hemorrhoids, hepatitis, hyperesthesia, hypoxia (children), increased creatine phosphokinase, increased intraocular pressure, increased liver enzymes, increased serum creatinine, intestinal obstruction, intracranial hemorrhage, iron deficiency, ischemia, jaundice, joint effusion, liver steatosis, malignant hyperthermia, menstrual disease (polymenorrhea), migraine, myocardial infarction, necrotizing enterocolitis (neonates), nephrolithiasis, neuritis, nodule (pulmonary), oligomenorrhea, orthostatic hypotension, pancreatitis, pancytopenia, paranoia, paresis, petechia, pituitary apoplexy, pleural effusion, pneumonia, pneumothorax, polyp (gallbladder), prolonged Q-T interval on ECG, pulmonary embolism, pulmonary hypertension, Raynaud&rsquo;s phenomenon, rectal hemorrhage, renal failure, renal insufficiency, scotoma, seizure, status asthmaticus, syncope, tachycardia, thrombocytopenia, thrombophlebitis, thrombosis (including retinal vein), urticaria, vaginitis, visual field defect, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202936\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to octreotide or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202919\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abnormal Schillings test: Chronic treatment has been associated with abnormal Schillings test; monitor vitamin B<sub>12</sub> levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholelithiasis: May impair gallbladder function (inhibits gallbladder contractility and decreases bile secretion); monitor patients for cholelithiasis. The incidence of gallbladder stone or biliary sludge increases with a duration of therapy of &ge;12 months. Prophylactic cholecystectomy is recommended in patients with gastrointestinal or pancreatic neuroendocrine tumors undergoing abdominal surgery if octreotide treatment is planned (Oberg 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose regulation: Somatostatin analogs may affect glucose regulation. In type I diabetes, severe hypoglycemia may occur; in type II diabetes or patients without diabetes, hyperglycemia may occur. Insulin and other hypoglycemic medication requirements may change. Octreotide may worsen hypoglycemia in patients with insulinomas; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local reactions: Mild to moderate injection-site pain (usually lasting 1 hour) may occur with the depot formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Suppresses secretion of TSH; monitor for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: May alter absorption of dietary fats; monitor for pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure or concomitant medications that alter heart rate or rhythm; bradycardia, conduction abnormalities, and arrhythmia have been observed in acromegalic and carcinoid syndrome patients. Cardiovascular medication requirements may change.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Excessive fluid loss: May reduce excessive fluid loss in patients with conditions that cause such a loss; periodic monitoring for elevations in zinc levels is recommended in such patients that are maintained on total parenteral nutrition (TPN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with hepatic impairment; dosage adjustment may be required in patients with established cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required in patients receiving dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QTc-prolonging agents: Octreotide may enhance the adverse/toxic effects of other QTc-prolonging agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depot formulation: Do not use depot formulation for the treatment of sulfonylurea-induced hypoglycemia (Dougherty 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vehicle used in depot injection (polylactide-co-glycolide microspheres): Has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Dosage adjustment may be necessary; significant increases in elimination half-life have been observed in older adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females: Therapy may restore fertility; females of childbearing potential should use adequate contraception.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Postmarketing cases of serious and fatal events, including hypoxia and necrotizing enterocolitis, have been reported with octreotide use in children (usually with serious underlying conditions), particularly in children &lt;2 years of age. In studies with octreotide depot, the incidence of cholelithiasis in children is higher than the reported incidences for adults and efficacy was not demonstrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiolabeled diagnostic evaluations: Therapy with immediate release octreotide (solution) should be withheld 24 hours prior to administration of radiolabeled somatostatin analogs; the IM (depot) formulation should be withheld at least 2 months before administration of radiolabeled somatostatin analogs (Oberg 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26019430\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The incidence of gallbladder stone or increase in sludge is ~33% in children with a duration of therapy &ge;12 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299780\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202924\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12655&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: Somatostatin Analogs may decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gallium Ga 68 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs.  Management: Imaging with gallium Ga 68 dotatate positron emission tomography (PET) should be performed just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lutetium Lu 177 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended.  Management: Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each lutetium Lu 177 dotatate dose. Administer short- and long-acting octreotide during treatment as recommended. See full monograph.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Somatostatin Analogs may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telotristat Ethyl: Octreotide may decrease the serum concentration of Telotristat Ethyl.  Management: Administer short-acting octreotide at least 30 minutes after administration of telotristat ethyl and monitor for decreased telotristat ethyl efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2998098\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Octreotide may alter absorption of dietary fats. Management: Administer injections between meals to decrease GI effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202926\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1791383\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Octreotide crosses the placenta and can be detected in the newborn at delivery (Caron 1995; Fassnacht 2001; Maffei 2010); data concerning use in pregnancy is limited. In case reports of acromegalic women who received normal doses of octreotide during pregnancy, no congenital malformations were reported. Because normalization of IGF-1 and GH may restore fertility in women with acromegaly, women of childbearing potential should use adequate contraception during treatment. Long-acting formulations should be discontinued ~2 months prior to a planned pregnancy; use short acting octreotide as needed until conception. Octreotide therapy may be considered in pregnant women with worsening symptoms if needed. Monitoring of IGF-1 and/or GH is not recommended during pregnancy (Katznelson 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060640\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and periodic ultrasound evaluations for cholelithiasis, blood sugar, baseline and periodic thyroid function tests, fluid and electrolyte balance, fecal fat, and serum carotene determinations; for carcinoid, monitor urinary 5-hydroxyindole acetic acid (5-HIAA), plasma serotonin, plasma substance P; for VIPoma, monitor VIP; vitamin B<sub>12</sub> levels (chronic therapy); for acromegaly: growth hormone levels, IGF-I (somatomedin C), glycemic control, and antidiabetic regimen (patients with diabetes mellitus)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060643\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Vasoactive intestinal peptide (VIP): &lt;75 ng/L; levels vary considerably between laboratories; growth hormone level: &lt;5 ng/mL; IGF-I (somatomedin C): males: &lt;1.9 units/mL, females: &lt;2.2 units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202918\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mimics natural somatostatin by inhibiting serotonin release, and the secretion of gastrin, VIP, insulin, glucagon, secretin, motilin, and pancreatic polypeptide. Decreases growth hormone and IGF-1 in acromegaly. Octreotide provides more potent inhibition of growth hormone, glucagon, and insulin as compared to endogenous somatostatin. Also suppresses LH response to GnRH, secretion of thyroid-stimulating hormone and decreases splanchnic blood flow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202935\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: SubQ: 6 to 12 hours; when using Sandostatin LAR Depot formulation, steady-state levels are achieved after 3 injections (3 months of therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: SubQ: Rapid and complete; IM (depot formulation): Released slowly (via microsphere degradation in the muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 14 L (21.6 &plusmn; 8.5 L in acromegaly)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 65%, primarily to lipoprotein (41% in acromegaly)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 100%; IM: 60% to 63% of SubQ dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1.7 to 1.9 hours; Increased in elderly patients; Cirrhosis: Up to 3.7 hours; Fatty liver disease: Up to 3.4 hours; Renal impairment: Up to 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: SubQ: 0.4 hours (0.7 hours acromegaly); IM: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (32% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Adults: 10 L/hour; Adults with acromegaly: 18 L/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202938\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (SandoSTATIN LAR Depot Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $3,737.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $4,897.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $7,333.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Octreotide Acetate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/mL (1 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (1 mL): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/mL (5 mL): $81.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/mL (5 mL): $288.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SandoSTATIN Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/mL (1 mL): $16.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (1 mL): $32.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $155.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/mL (5 mL): $1,634.11</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869399\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cryostatin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Nomactril (MX);</li>\n      <li>Octide (ID, TW);</li>\n      <li>Octostat (LK);</li>\n      <li>Octride (CO, LK, PH);</li>\n      <li>Oktra (UA);</li>\n      <li>Proclose (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Sandostatin (AE, AR, AT, AU, BB, BD, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, GB, GR, HK, HN, HR, ID, IE, IL, IN, IQ, IR, IS, JO, JP, KR, KW, LB, LK, LT, LU, LV, LY, MT, MY, NO, NZ, OM, PE, PH, PK, PL, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Sandostatin LAR (AE, AR, AU, BG, BH, BR, CH, CL, CN, CU, CY, EE, ES, HR, ID, IL, IS, JP, KR, LB, LK, LT, LU, LV, MT, MY, NO, NZ, PE, PH, PY, RO, SA, SE, SG, SI, SK, TH, TW, UY, VN);</li>\n      <li>Sandostatina (IT, MX, PT);</li>\n      <li>Sandostatina LAR (CO);</li>\n      <li>Sandostatine (BE, FR, NL);</li>\n      <li>Sandostatyn (UA);</li>\n      <li>Sandostatyn LAR (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Battershill PE, Clissold SP. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. <i>Drugs</i>. 1989;38(5):658-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/2689136/pubmed\" target=\"_blank\" id=\"2689136\">2689136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beckman RA, Siden R, Yanik GA, et al, &ldquo;Continuous Octreotide Infusion for the Treatment of Secretory Diarrhea Caused by Acute Intestinal Graft-Versus-Host Disease in a Child,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2000, 22(4):344-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/10959906/pubmed\" target=\"_blank\" id=\"10959906\">10959906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calello DP, Osterhoudt KC, Henretig FM, et al, &quot;Octreotide for Pediatric Sulfonylurea Overdose: Review of 5 Cases,&quot; <i>Clin Toxicol</i>, 2005, 43:671. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caron P, Gerbeau C, Pradayrol L. Maternal-fetal transfer of octreotide. <i>N Engl J Med</i>. 1995;333(9):601-602. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/7623921/pubmed\" target=\"_blank\" id=\"7623921\">7623921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan SY, Lau W, Wong WH, et al, &quot;Chylothorax in Children After Congenital Heart Surgery,&quot; <i>Ann Thorac Surg</i>, 2006, 82(5):1650-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/17062221/pubmed\" target=\"_blank\" id=\"17062221\">17062221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheung Y, Leung MP, and Yip M, &ldquo;Octreotide for Treatment of Postoperative Chylothorax,&rdquo; <i>J Pediatr</i>, 2001, 139(1):157-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/11445812/pubmed\" target=\"_blank\" id=\"11445812\">11445812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couper RT, Berzen A, Berall G, et al, &ldquo;Clinical Response to the Long-Acting Somatostatin Analogue SMS 201-995 in a Child With Congenital Microvillus Atrophy,&rdquo; <i>Gut</i>, 1989, 30(7):1020-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/2759484/pubmed\" target=\"_blank\" id=\"2759484\">2759484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Das A and Shah PS, &quot;Octreotide for the Treatment of Chylothorax in Neonates,&quot; <i>Cochrane Database Syst Rev</i>, 2010, 9:CD006388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/20824848/pubmed\" target=\"_blank\" id=\"20824848\">20824848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eroglu Y, Emerick KM, Whitingon PF, et al, &quot;Octreotide Therapy for Control of Acute Gastrointestinal Bleeding in Children,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 38(1):41-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/14676593/pubmed\" target=\"_blank\" id=\"14676593\">14676593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fasano CJ, O'Malley G, Dominici P, et al, &quot;Comparison of Octreotide and Standard Therapy Versus Standard Therapy Alone for the Treatment of Sulfonylurea-Induced Hypoglycemia,&quot; <i>Ann Emerg Med</i>, 2008, 51(4):400-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/17764782/pubmed\" target=\"_blank\" id=\"17764782\">17764782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fassnacht M, Capeller B, Arlt W, et al. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. <i>Clin Endocrinol (Oxf)</i>. 2001;55(3):411-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/11589686/pubmed\" target=\"_blank\" id=\"11589686\">11589686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaros W, Biller J, Greer S, et al, &ldquo;Successful Treatment of Idiopathic Secretory Diarrhea of Infancy With the Somatostatin Analogue SMS 201-995,&rdquo; <i>Gastroenterology</i>, 1988, 94(1):189-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/2891583/pubmed\" target=\"_blank\" id=\"2891583\">2891583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz MD and Erstad BL, &ldquo;Octreotide, A New Somatostatin Analogue,&rdquo; <i>Clin Pharm</i>, 1989, 8(4):255-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/2653711 /pubmed\" target=\"_blank\" id=\"2653711 \">2653711 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/25356808 /pubmed\" target=\"_blank\" id=\"25356808 \">25356808 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalomenidis I, &quot;Octreotide and chylothorax,&quot; Curr Opin Pulm Med, 2006, 12(4):264-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/16825878/pubmed\" target=\"_blank\" id=\"16825878\">16825878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugassy DM, Nelson LS, Hoffman RS, et al, &quot;Failure of Standard Octreotide Dosing to Prevent Recurrent Hypoglycemia Following Sulfonylurea Exposure in a Child,&quot; <i>J Toxicol Clin Toxicol</i>, 2009, 47(7):760. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lustig RH, Hinds PS, Ringwald-Smith K, et al, &quot;Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial,&quot; <i>J Clin Endocrinol Metab</i>, 2003, 88(6):2586-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/12788859/pubmed\" target=\"_blank\" id=\"12788859\">12788859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maffei P, Tamagno G, Nardelli GB, et al. Effects of octreotide exposure during pregnancy in acromegaly. <i>Clin Endocrinol (Oxf)</i>. 2010;72(5):668-677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/19769624/pubmed\" target=\"_blank\" id=\"19769624\">19769624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin SA, Crandall CS, and McKinney PE, &quot;Octreotide: An Antidote for Sulfonylurea-Induced Hypoglycemia,&quot; <i>Ann Emerg Med</i>, 2000, 36(2):133-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/10918104/pubmed\" target=\"_blank\" id=\"10918104\">10918104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mordel A, Sivilotti ML, Old AC, et al, &quot;Octreotide for Pediatric Sulfonylurea Poisoning,&quot; <i>J Toxicol Clin Toxicol</i>, 1998, 36(5):437. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;:  Palliative Care,&rdquo; Version 2.2011. Available at  http://www.nccn.org/professionals/physician_gls/PDF/palliative.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pratap U, Slavik Z, Ofoe VD, et al, &ldquo;Octreotide to Treat Postoperative Chylothorax After Cardiac Operations in Children,&rdquo; <i>Ann Thorac Surg</i>, 2001, 72(5):1740-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/11722081 /pubmed\" target=\"_blank\" id=\"11722081 \">11722081 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roehr CC, Jung A, Proquitt&eacute; H, et al, &quot;Somatostatin or Octreotide as Treatment Options for Chylothorax in Young Children: A Systematic Review,&quot; <i>Intensive Care Med</i>, 2006, 32(5):650-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/16532329/pubmed\" target=\"_blank\" id=\"16532329\">16532329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siafakas C, Fox VL, and Nurko S, &ldquo;Use of Octreotide for the Treatment of Severe Gastrointestinal Bleeding in Children,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 1998, 26(3):356-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/ 9523876 /pubmed\" target=\"_blank\" id=\" 9523876 \"> 9523876 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stanley CA, &ldquo;Hyperinsulinism in Infants and Children,&rdquo; <i>Pediatr Clin North Am</i>, 1997, 44(2):363-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/ 9130925 /pubmed\" target=\"_blank\" id=\" 9130925 \"> 9130925 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang J and Weiter JJ, &quot;Branch Retinal Artery Occlusion After Injection of a Long-Acting Risperidone Preparation,&quot; <i>Ann Intern Med</i>, 2007, 147(4):283-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/octreotide-pediatric-drug-information/abstract-text/17709768/pubmed\" target=\"_blank\" id=\"17709768\">17709768</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12655 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202953\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202954\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060641\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675255\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060634\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202929\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202915\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060645\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F202949\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060644\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203010\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4370122\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202936\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202919\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26019430\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299780\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202924\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F2998098\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202926\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1791383\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060640\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1060643\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202918\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202935\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202938\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869399\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12655|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">Octreotide: Drug information</a></li><li><a href=\"topic.htm?path=octreotide-patient-drug-information\" class=\"drug drug_patient\">Octreotide: Patient drug information</a></li></ul></div></div>","javascript":null}